IOVA (Iovance Biotherapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on IOVA (Iovance Biotherapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock m

IOVA

Iovance Biotherapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
Nov 11, 2025
IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
Nov 7, 2025
Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound
Nov 7, 2025
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates
Nov 6, 2025
Iovance Biotherapeutics: Q3 Earnings Snapshot
Nov 6, 2025
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
Nov 6, 2025
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
Nov 3, 2025
Iovance Biotherapeutics (IOVA): Exploring Valuation After a Prolonged Share Price Decline
Oct 23, 2025
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
Oct 23, 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 17, 2025
Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls
Oct 6, 2025
Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts
Sep 20, 2025

Reviews